Search clinical trials for: AZD9833 placebo

Total 53728 results

AstraZeneca
Quotient Sciences

Completed

A Study to Assess the Rel Bioavailability, Food Effect and Absolute Bioavailability on the Pharmacokinetics of AZD9833

Healthy Volunteers

United Kingdom
AstraZeneca

Active, not recruiting

A Phase 1 Study of AZD9833 in Japanese Women With ER Positive, HER2 Negative Advanced Breast Cancer

ER+ HER2- Advanced Breast Cancer

Japan
AstraZeneca
Parexel

Recruiting

A Study to Investigate Safety, Tolerability, and Pharmacokinetics of Oral AZD0233 Compared With Placebo in Healthy Adult Participants.

Dilated Cardiomyopathy

United States
AstraZeneca

Completed

Assessment of Safety, Tolerability and Blood Concentrations of Single Doses of AZD3839 in Healthy Volunteers

Healthy Volunteers | Alzheimer's Disease | Tolerability | Safety | Blood Concentration

United Kingdom
AstraZeneca

Terminated

A Study to Assess the Safety and Tolerability of Single and Multiple Doses of AZD4831 in Healthy Male Subjects

Cardiovascular Disease
AstraZeneca

Completed

Study to Investigate Hepatic Impairment on PK, Safety, Tolerability of Camizestrant in Post-Menopausal Female Subjects

Hepatic Impairment

United States, Bulgaria, Slovakia
AstraZeneca

Completed

Study to Evaluate the Efficacy and Safety of AZD4831 in Participants With Heart Failure With Left Ventricular Ejection Fraction > 40% (ENDEAVOR)

Heart Failure With Preserved Ejection Fraction

United States, France, Netherlands, Belgium, Taiwan, Slovakia, Japan, Czechia, Hungary, Australia, Bulgaria, Poland, Russian Federation, Brazil, Denmark, Turkey, Sweden, Canada
AstraZeneca
Parexel

Completed

A Study to Assess the Effect AZD4831 in Japanese and Chinese Healthy Volunteers

Heart Failure With Preserved Ejection Fraction (HFpEF)

United States
AstraZeneca

Terminated

Safety and Tolerability Study of AZD4831 in Patients With Heart Failure. (SATELLITE)

Heart Failure

Denmark, Finland, Netherlands, United States, Sweden
AstraZeneca

Completed

A Study in Participants With Non-cirrhotic NASH With Fibrosis (COSMOS)

Non-Cirrhotic Non-alcoholic Steatohepatitis With Fibrosis

Denmark, Italy, Spain, United States, Argentina, Sweden, Mexico, Norway, Portugal
AstraZeneca
Parexel

Completed

A Phase I, Safety Tolerability and Pharmacokinetics of AZD4831 to Treat Cardiovascular Disease

Cardiovascular Disease

United States
AstraZeneca

Completed

AZD0837 Extended Release (ER) Japan Study (ER J ph I)

Healthy

Japan
AstraZeneca

Active, not recruiting

Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer. (SERENA-1)

ER+ HER2- Advanced Breast Cancer

United States, Spain, United Kingdom
AstraZeneca

Active, not recruiting

An Efficacy and Safety Study of Mitiperstat (AZD4831) (MPO Inhibitor) vs Placebo in the Treatment of Moderate to Severe COPD. (CRESCENDO)

Chronic Obstructive Pulmonary Disease (COPD)

United States, Denmark, Italy, United Kingdom, Canada, Germany, Turkey, Argentina, South Africa, Spain, Poland, Bulgaria, Mexico, Netherlands
AstraZeneca

Completed

AZD9773 Dose Escalation Study

Severe Sepsis

United States
AstraZeneca

Completed

A Study to Investigate the Biological Effects of AZD9833 in Women With ER-positive, HER2 Negative Primary Breast Cancer (SERENA-3)

HER2-negative Breast Cancer

Mexico, United Kingdom, Georgia
AstraZeneca
Parexel

Terminated

A Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of AZD9898

Asthma

United Kingdom
Mayo Clinic
National Center for Advancing Translational Sciences (NCATS)

Completed

MPO Inhibitor A_Zeneca for HFpEF

Heart Failure

United States
AstraZeneca

Completed

A Study to Compare the Efficacy and Safety of 2 Dosing Regimens of IV Infusions of AZD9773 (CytoFab™) With Placebo in Adult Patients With Severe Sepsis and/or Septic Shock

Septic Shock | Severe Sepsis

Czech Republic, France, Spain, Finland, Canada, Australia, Belgium
AstraZeneca
Parexel

Completed

To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD8233 After Multiple Dose Administration in Subjects With Dyslipidemia

Dyslipidemia

United States
AstraZeneca

Completed

AZD9833 China PK Study (AZD9833)

ER+, HER2-, Metastatic Breast Cancer

China
AstraZeneca

Completed

A Study to Assess the Safety, Efficacy and Tolerability of AZD8233 Treatment in Participants With Hyperlipidaemia (SOLANO)

Hyperlipidaemia

Denmark, Netherlands, Spain, Czechia, United States, Slovakia, Hungary, Poland
AstraZeneca

Completed

A Study of AZD8233 in Participants With Dyslipidemia. (HAYATE)

Dyslipidemia

Japan
AstraZeneca

Completed

A Study of AZD8233 in Participants With Dyslipidemia

Dyslipidaemia

Denmark, United States, Slovakia
AstraZeneca
Quotient Sciences

Completed

A Study to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]AZD9833

ER-positive, HER2-negative Breast Cancer

United Kingdom
AstraZeneca

Terminated

Evaluation of Drug Activity in Women With Breast Cancer and no Previous Herceptin Treatment (CHIVE)

Breast Neoplasm

Korea, Republic of, Germany, Taiwan
AstraZeneca

Recruiting

Study of AZD9829 in CD123+ Hematological Malignancies

Hematological Malignancies

United States, Spain, Korea, Republic of, Italy, Japan, Taiwan, Australia, Germany, China
AstraZeneca
Parexel

Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD8233 in Healthy Male Subjects With Increased Elevated LDL-C Levels.

Hypercholesterolemia

United States
AstraZeneca

Completed

A Study to Assess Safety,and Tolerability of 2 Doses of AZD9773 (CytoFab™) in Japanese With Severe Sepsis/Septic Shock

Septic Shock | Severe Sepsis

Japan
AstraZeneca

Completed

Single Centre, Double-blind, Single and Multiple Ascending Inhaled Doses of AZD9819 in Healthy Subjects

Healthy Volunteers | Tolerability | Safety

United Kingdom
AstraZeneca
Parexel

Terminated

To Assess the Pharmacokinetics, Safety, and Tolerability of AZD8233 in Participants With Chronic Kidney Disease (CKD), End Stage Renal Disease (ESRD) and Healthy Participants.

End Stage Renal Disease

Poland
AstraZeneca
Parexel

Completed

A Study to Assess the Relative Bioavailability and Safety of Different Formulations of AZD4831 in Fasted State in Healthy Volunteers.

Healthy Volunteers

United States
AstraZeneca

Completed

Study of AZD8931 in Patients With Advanced Solid Malignancies

Advanced Solid Malignancies

Russian Federation, Germany
AstraZeneca

Completed

A Study to Determine the Effect of Food on the Pharmacokinetics of Oral AZD8931 Tablets

Healthy

United Kingdom
AstraZeneca

Completed

Pharmacokinetics of Extended-Release Test- and Reference Formulations of AZD0837

Healthy

Sweden
AstraZeneca
Parexel

Completed

A Study to Assess the Pharmacokinetics (Uptake of Drugs by the Body), Safety and Tolerability of AZD4831 in Participants With Severe Renal Impairment and Healthy Volunteers

Renal Impairment

Bulgaria
AstraZeneca

Completed

A Study to Compare Two Different Tablet Formulations of AZD8931 in Healthy Males and Females

Healthy

United Kingdom
AstraZeneca

Completed

Healthy Volunteers, Absorption, Distribution, Metabolism and Excretion (ADME) Study With Single Oral Administration of [14C] AZD8931

Healthy

United Kingdom
AstraZeneca

Completed

AZD8330 First Time in Man in Patients With Advanced Malignancies

Cancer

United States, Norway
AstraZeneca

Active, not recruiting

A Randomized Trial Evaluating a mRNA-VLP Vaccine's Immunogenicity and Safety for COVID-19 (ARTEMIS-C)

COVID-19 | SARS-CoV-2 Infection

United States
AstraZeneca
Quotient Sciences

Completed

A Study to Assess the Mass Balance Recovery, Pharmacokinetics, Metabolite Profile and Metabolite Identification of [14C]AZD4831

Cardiovascular Disease

United Kingdom
AstraZeneca

Recruiting

Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6) (SERENA-6)

ER-Positive HER2-Negative Breast Cancer

United States, Israel, Spain, Korea, Republic of, Italy, Poland, Belgium, Norway, Bulgaria, France, Germany, United Kingdom, Japan, Taiwan, Canada, Hungary, Australia, Austria, Portugal, Turkey, Russian Federation, Slovakia, Switzer...
AstraZeneca

Active, not recruiting

A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease (SERENA-4)

ER-Positive HER2-Negative Breast Cancer

Austria, Belgium, France, Germany, Italy, United Kingdom, United States, Canada, India, Taiwan, Russian Federation, Korea, Republic of, Hungary, Japan, Mexico, Turkey, China, Malaysia, Spain, Czechia, Portugal, Poland, Norway, Bulgaria, Slovaki... and more
AstraZeneca

Recruiting

Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors

Gastric Cancer | Pancreatic Ductal Adenocarcinoma | Esophageal Adenocarcinoma | Gastro-esophageal Junction Cancer

Korea, Republic of, United States, Japan, Taiwan, China, United Kingdom, Netherlands
Takeda
Eli Lilly and Company

Completed

Efficacy of Pioglitazone on Macrovascular Outcome in Patients With Type 2 Diabetes (PROactive)

Diabetes Mellitus

Estonia, Latvia, Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Hungary, Italy, Lithuania, Netherlands, Norway, Poland, Slovakia, Sweden, Switzerland, United Kingdom
Takeda

Completed

Efficacy of Pioglitazone on Microcirculation in Type 2 Diabetes Patients Treated With Insulin

Diabetes Mellitus

United Kingdom
AstraZeneca

Completed

Excretion of Radiolabelled AZD0837

Healthy

Sweden
Takeda

Completed

Efficacy of Pioglitazone on Myocardial Function in Patients Undergoing Coronary Stent Implantation.

Coronary Artery Disease | Type 2 Diabetes | Oxidative Stress

Germany
AstraZeneca

Recruiting

Pharmacokinetics of Mitiperstat in Participants With Hepatic Impairment

Hepatic Impairment

United States
Takeda

Terminated

Efficacy and Safety of TAK-379 in Adult Subjects With Type 2 Diabetes Mellitus

Diabetes Mellitus

United States

3

Subscribe